Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Research Report 2023

Publication ID:

PB510237433

Publication Date:

October 25, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Human Chorionic Gonadotrophin (HCG) is a hormone produced during pregnancy. It is used as an indicator in pregnancy tests and can also be administered medically for various purposes.
The global Human Chorionic Gonadotrophin (HCG) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Human Chorionic Gonadotrophin (HCG) market research.
Key companies engaged in the Human Chorionic Gonadotrophin (HCG) industry include Qingdao Kangyuan Pharmaceutical Co., Ltd., Ningbo Renjian Pharmaceutical Group Co., Ltd., Jiangxi Haoran Biopharmaceutical Co., Ltd. and Shanghai Tianwei Biopharmaceutical Co., Ltd., etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Human Chorionic Gonadotrophin (HCG) were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Human Chorionic Gonadotrophin (HCG) market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Human Chorionic Gonadotrophin (HCG) market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Qingdao Kangyuan Pharmaceutical Co., Ltd.
Ningbo Renjian Pharmaceutical Group Co., Ltd.
Jiangxi Haoran Biopharmaceutical Co., Ltd.
Shanghai Tianwei Biopharmaceutical Co., Ltd.
Segment by Type
u-hCG
r-hCG
Segment by Application
Drug
Pregnancy Test Paper
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Human Chorionic Gonadotrophin (HCG) report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 u-hCG
1.2.3 r-hCG
1.3 麻豆原创 by Application
1.3.1 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Drug
1.3.3 Pregnancy Test Paper
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Perspective (2018-2029)
2.2 Human Chorionic Gonadotrophin (HCG) Growth Trends by Region
2.2.1 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Human Chorionic Gonadotrophin (HCG) Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Human Chorionic Gonadotrophin (HCG) Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Dynamics
2.3.1 Human Chorionic Gonadotrophin (HCG) Industry Trends
2.3.2 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Drivers
2.3.3 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Challenges
2.3.4 Human Chorionic Gonadotrophin (HCG) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Human Chorionic Gonadotrophin (HCG) Players by Revenue
3.1.1 Global Top Human Chorionic Gonadotrophin (HCG) Players by Revenue (2018-2023)
3.1.2 Global Human Chorionic Gonadotrophin (HCG) Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Human Chorionic Gonadotrophin (HCG) Revenue
3.4 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Concentration Ratio
3.4.1 Global Human Chorionic Gonadotrophin (HCG) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Human Chorionic Gonadotrophin (HCG) Revenue in 2022
3.5 Human Chorionic Gonadotrophin (HCG) Key Players Head office and Area Served
3.6 Key Players Human Chorionic Gonadotrophin (HCG) Product Solution and Service
3.7 Date of Enter into Human Chorionic Gonadotrophin (HCG) 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Human Chorionic Gonadotrophin (HCG) Breakdown Data by Type
4.1 Global Human Chorionic Gonadotrophin (HCG) Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Human Chorionic Gonadotrophin (HCG) Forecasted 麻豆原创 Size by Type (2024-2029)
5 Human Chorionic Gonadotrophin (HCG) Breakdown Data by Application
5.1 Global Human Chorionic Gonadotrophin (HCG) Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Human Chorionic Gonadotrophin (HCG) Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size (2018-2029)
6.2 North America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2018-2023)
6.4 North America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size (2018-2029)
7.2 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2018-2023)
7.4 Europe Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size (2018-2029)
9.2 Latin America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Human Chorionic Gonadotrophin (HCG) 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Qingdao Kangyuan Pharmaceutical Co., Ltd.
11.1.1 Qingdao Kangyuan Pharmaceutical Co., Ltd. Company Detail
11.1.2 Qingdao Kangyuan Pharmaceutical Co., Ltd. Business Overview
11.1.3 Qingdao Kangyuan Pharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Introduction
11.1.4 Qingdao Kangyuan Pharmaceutical Co., Ltd. Revenue in Human Chorionic Gonadotrophin (HCG) Business (2018-2023)
11.1.5 Qingdao Kangyuan Pharmaceutical Co., Ltd. Recent Development
11.2 Ningbo Renjian Pharmaceutical Group Co., Ltd.
11.2.1 Ningbo Renjian Pharmaceutical Group Co., Ltd. Company Detail
11.2.2 Ningbo Renjian Pharmaceutical Group Co., Ltd. Business Overview
11.2.3 Ningbo Renjian Pharmaceutical Group Co., Ltd. Human Chorionic Gonadotrophin (HCG) Introduction
11.2.4 Ningbo Renjian Pharmaceutical Group Co., Ltd. Revenue in Human Chorionic Gonadotrophin (HCG) Business (2018-2023)
11.2.5 Ningbo Renjian Pharmaceutical Group Co., Ltd. Recent Development
11.3 Jiangxi Haoran Biopharmaceutical Co., Ltd.
11.3.1 Jiangxi Haoran Biopharmaceutical Co., Ltd. Company Detail
11.3.2 Jiangxi Haoran Biopharmaceutical Co., Ltd. Business Overview
11.3.3 Jiangxi Haoran Biopharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Introduction
11.3.4 Jiangxi Haoran Biopharmaceutical Co., Ltd. Revenue in Human Chorionic Gonadotrophin (HCG) Business (2018-2023)
11.3.5 Jiangxi Haoran Biopharmaceutical Co., Ltd. Recent Development
11.4 Shanghai Tianwei Biopharmaceutical Co., Ltd.
11.4.1 Shanghai Tianwei Biopharmaceutical Co., Ltd. Company Detail
11.4.2 Shanghai Tianwei Biopharmaceutical Co., Ltd. Business Overview
11.4.3 Shanghai Tianwei Biopharmaceutical Co., Ltd. Human Chorionic Gonadotrophin (HCG) Introduction
11.4.4 Shanghai Tianwei Biopharmaceutical Co., Ltd. Revenue in Human Chorionic Gonadotrophin (HCG) Business (2018-2023)
11.4.5 Shanghai Tianwei Biopharmaceutical Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Qingdao Kangyuan Pharmaceutical Co., Ltd.
Ningbo Renjian Pharmaceutical Group Co., Ltd.
Jiangxi Haoran Biopharmaceutical Co., Ltd.
Shanghai Tianwei Biopharmaceutical Co., Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.